Bryce Canyon National Park
Early 1980s
It is pretty interesting how many “alerts” to OVCA articles
turn out to be in business/financial/stockmarket publications. I guess it is obvious why this should be; any
pharma company that is likely to bring a
“breakthrough” drug to market is a hot commodity on the Street. This annoys me somewhat, but irrationally. Yes, Jesus kicked the money-changers out of
the temple, but what if they were making change for people who wanted to
donate? Profit isn’t always bad, no
matter what you think.
However, the article that inspired this rambling, which
appeared in TheStreet.com, has some interesting news. It appears that Clovis Oncology (NASDAQ:
CLVS) has a drug called rucaparib that is sufficiently promising that it has
been awarded the designation of Breakthrough Therapy by the FDA. (What that means doesn’t seem to have been
explained, but I’ll bet it’s good). Rucaparib
is an oral PARP inhibitor (you remember those guys, right?). It seems to be used with good effect on
cancers caused by BRCA mutations. And,
of course, it merely prolongs life – it isn’t a cure. But what the hell, it’s progress.
Read the article, but don’t buy the stock.
No comments:
Post a Comment